Takayasu's arteritis
Methodology & AI Transparency ⓘ
Takayasu's arteritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Takayasu's arteritis—coded clinically as M31.4 across Arthritis & Joints guidelines—combines serum urate/inflammatory marker in Takayasu's arteritis (M31.4: profiling) with structured follow-up of Serum Uric Acid in Takayasu's arteritis (M31.4: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.4)).
- 2 Real-world patient consensus: Clinical coding for Takayasu's arteritis uses ICD-10 M31.4 across Arthritis & Joints specialty care.
- 3 Typical cash cost range: Primary evaluation for Takayasu's arteritis incorporates serum urate/inflammatory marker in Takayasu's arteritis (M31.4: profiling) and symptom diary review.
- 4 Top reported side effects / signs: Objective lab/clinical target for Takayasu's arteritis: Weight-Bearing Joint Radiograph [Takayasu's arteritis M31.4] (Preserved joint-space width (M31.4)) and Serum Uric Acid in Takayasu's arteritis (M31.4: (Gout Target)).
Ask our AI Specialists anything about Takayasu's arteritis
What Is Takayasu's arteritis?
Takayasu's arteritis—coded clinically as M31.4 across Arthritis & Joints guidelines—combines serum urate/inflammatory marker in Takayasu's arteritis (M31.4: profiling) with structured follow-up of Serum Uric Acid in Takayasu's arteritis (M31.4: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.4)).
Pathophysiology, Underlying Causes & Clinical Presentation
At the cellular and tissue level in arthritis & joints, Takayasu's arteritis (M31.4) involves monosodium urate or in Takayasu's arteritis (M31.4: calcium pyrophosphate crystal). progression correlates with shifts in Weight-Bearing Joint Radiograph [Takayasu's arteritis M31.4] (Preserved joint-space width (M31.4)).
Common Symptoms & Clinical Signs
- • Presentation of Takayasu's arteritis (M31.4): localized tendon or in Takayasu's arteritis (M31.4: bursa tenderness limiting)
- • Secondary Takayasu's arteritis clinical sign: activity-related deep aching in Takayasu's arteritis (M31.4: joint pain in)
- • Symptom flares in Takayasu's arteritis correlating with Weight-Bearing Joint Radiograph [Takayasu's arteritis M31.4] deviation outside Preserved joint-space width (M31.4)
- • Functional arthritis & joints impact requiring serum urate/inflammatory marker in Takayasu's arteritis (M31.4: profiling) evaluation (M31.4)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Takayasu's arteritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M31.4 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Takayasu's arteritis M31.4] | Preserved joint-space width (M31.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Serum Uric Acid in Takayasu's arteritis (M31.4: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M31.4) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Takayasu's arteritis (M31.4: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M31.4) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Takayasu's arteritis
Treatment selection for Takayasu's arteritis depends on clinical severity, diagnostic lab results, and medical history. Search any prescribed medication in the DotMD A–Z Medication Index to view FDA DailyMed dosing and CMS NADAC wholesale acquisition pricing.
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Takayasu's arteritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Deciphering differential biomarkers for anti-interleukin-6 receptor and: What a 804-Participant Study Found The unbiased analysis of serum proteins identified biomarkers most predictive of anti-IL-6R and anti-TNF-α at different timepoints that could explain the difference in the response rate in patients with RA. RMD open • 2025-08-04 • Phase III Randomized Trial | N = 804 | 93/100 | PMID 40759562 ↗ |
| Can This Approach Help? Inside the Latest Research on Promising efficacy of coenzyme Q10 supplementation as add-on treatment in CoQ10 significantly improved disease severity, QoL, and inflammatory and oxidative stress markers in JIA patients with an excellent safety profile. Immunopharmacology and immunotoxicology • 2026-06-15 • Phase III Randomized Trial | N = 58 | 88/100 | PMID 41958203 ↗ |
| Can This Approach Help? Inside the Latest Research on Benefits and safety of curcumin in maintaining full symptom relief during No serious adverse effects were noted. Rheumatology international • 2023-12-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 37650921 ↗ |
| Can This Approach Help? Inside the Latest Research on Vascular imaging of patients with refractory Takayasu arteritis treated with Approximately 60% of patients with TAK did not experience progression in wall thickness within 96 weeks after initiation of tocilizumab treatment. Rheumatology (Oxford, England) • 2022-05-30 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 34528074 ↗ |
Takayasu's arteritis Patient Community & “People Like Me” Threads
Filter Takayasu's arteritis community threads and patient logs by age, biological sex, dosage, and treatment duration.